BioSpace News Archive

CVS Health Corporation announced that Eva Boratto, Executive Vice President and Chief Financial Officer, and Karen Lynch, Executive Vice President and President of Aetna, will be participating in a fireside chat with investors at the Goldman Sachs 41st Annual Healthcare Conference on June 10, 2020, at approximately 8:00 am ET.

Biomarck Pharmaceuticals, Ltd. , a biopharmaceutical company developing targeted anti-MARCKS technology for the treatment of ARDS [Acute Respiratory Distress Syndrome], cancer and other difficult to treat diseases, today announced new data from a Phase 2 study of its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), will be presented during the American Thoracic Society 2020 (ATS) virtual meeting

Dr. Krishna’s main responsibilities will be to assist and advise Ehave on human trials for its cognitive and psychedelic opportunities.

As a preferred provider, Confirm BioSciences will have an ample supply of COVID-19 IgG/IgM Rapid Test kits for medical professional use starting in May

Shanghai Henlius Biotech, Inc. (2696.HK) and Accord Healthcare Limited (Accord) jointly announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for biosimilar HLX02

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors for the purchase and sale of 2,510,286 of the Company’s American Depositary Shares (ADS

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced its Migraine Awareness Month $50 rebate for new Nerivio® prescriptions dispensed during June 2020.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and ot

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd , at 10:00 a.m. ET, and at the William Blair 40 th Annual Growth Stock Conference on Tuesday, June 9 th , at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments. A li